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Multiple osteochondromatosis, also known as hereditary multiple exostoses (HME), is an inherited autoso-
mal dominant disorder characterized by the presence of multiple exostoses on the long bones. These exostoses
are benign cartilaginous tumors (enchondromata). Three different exostosis (EXT) loci on chromosomes
8q (exostosin 1, EXT1), 11p (exostosin 2, EXT2) and 19p (exostosin 3, EXT3) have been reported. Recently,
the EXT1 and EXT2 genes were identified by positional cloning. Using polymerase chain reaction and direct
sequencing, we analyzed the EXT1 and EXT2 genes in three familial cases and one sporadic case of HME in
Taiwanese patients. We found three novel mutations (S277X in the EXT1 gene, and G194X and 939+1G>A in
the EXT2 gene) and a known mutation (Q172X in the EXT2 gene). Mutation analysis in families with HME
allows for genetic counseling and prenatal diagnosis. [J Formos Med Assoc 2006;105(5):434–437]
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Hereditary multiple exostoses (HME) is an au-
tosomal dominant disorder with an incidence of
1 in 50,0001 that makes it one of the most com-
mon inherited musculoskeletal disorders. Pene-
trance is estimated to be 100%.2 Approximately
20% of reported cases have no family history of
multiple exostoses. HME patients show multiple
benign exostoses, typically located at the juxta-
epiphyseal region of bones. The clinical symptoms
and signs may be occult and only radiologically
distinguishable, or may be accompanied by ske-
letal deformities and, sometimes, short stature.3
Exostoses are rarely present at birth, but gradual-
ly arise and increase in size in the first decade of
life.2 The most severe complication of HME is the
sarcomatous transformation of an osteochondro-
ma into a chondrosarcoma, which occurs in 0.5–
2% of patients with HME.1,2
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HME is a genetically heterogeneous disease
with at least three chromosomal loci: EXT1 (ex-
ostosin 1, 8q24.1, OMIM 133700),4 EXT2 (exosto-
sin 2, 11p11-p13, OMIM 133701),5,6 and EXT3
(exostosin 3, 19p, OMIM 600209).7 Mutations in
the EXT1 and EXT2 genes are involved in the patho-
genesis of HME.3–5,8,9 EXT1 and EXT2 mutations
were reported to be responsible for one-half and
one-third of HME cases, respectively.10
Here, we report the results of mutation analy-
sis in three familial and one sporadic case of HME
in Taiwanese.
Methods
Subjects
Three familial and one sporadic HME families were
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studied (Figure 1). All of the patients had received
operations, and pathology reports had confirmed
osteochondroma. Pedigrees were constructed and
family members were interviewed to cross check
historical phenotypic information. Genomic DNA
was extracted from the peripheral blood of each
patient; the patients’ parents gave informed con-
sent. DNA samples were subjected to mutation
screening by amplification of segments of the
EXT1 and EXT2 genes using primers synthesized
on the basis of intronic sequences (EXT1, GenBank
accession number NT_008046; EXT2, GenBank ac-
cession number NT_009237) (Table 1).
Polymerase chain reaction (PCR) amplification
was performed with approximately 200 ng of
genomic DNA, 12.8 pmol of each primer, 10 μM
Case 1
Case 3
Case 2
Case 4
Figure 1. Pedigrees of individuals with hereditary multiple exostoses. Solid symbol =
affected individual; open symbol = unaffected individual; square = male; circle = female;
arrow = proband.
Table 1. Primers used in mutation screening of the EXT1 and EXT2 genes
Forward primer 5’➔3’ Backward primer 5’➔3’ AT (°C) Product size (bp)
EXT1 gene
E1-1 ATGCAGGCCAAAAAACGCTA CATCAAAGTTGGGTCGGAAG 50 694
E1-2 GTGCAGAGTCTCCACTTGTG GATTTGCTCAGTTCCAGGCT 53 571
E2 GAAAAGTGAGAGCTGCCTGC GAGTAAATCCTCCCTCCACC 53 415
E3 CAGTCCAGGATTCATGCAGT AGCTCCCATTCTTTACCTGC 50 467
E4 CTCTTTGCAGCTGACACTTC CTCCCCATGTAGGTTTTCCT 50 519
E5 GTCACTACTCTGACTGCCAC GATGGACCCCATTAGAGTAG 50 333
E6 CATCTTGTTTCTGTCCTGTC CTTCCCTGTGCAGATTTCAC 50 481
E7 CTCAGTTTTGATGTCTGCCG CTATTGCCAGCTCCTGACTT 50 569
E8 GACATGATAGTAGCGCATTC CAACTGCTCACAACTGTGCT 50 516
E9 CACAGTCCCCGGATTTTGCA CTCAGTGATGAATCCCAAGC 53 615
E10 CTGCCTTGTAGGCTCCTTAT CTCCTCATTATATGCTCCTG 50 523
E11 CATAGATGGTGAGACTTGGT CTGTACACAACCTAGTCTTG 50 566
EXT2 gene
E1 ATGTGTGCGTCGGTCAAGTA CGGGAAACCAACTCAAGAGC 53 644
E2 CAGGAGTTTGCTTTGCATAC ATTCAGAGAGAGCTAGCACA 50 525
E3 CAAGGATAGAACGCAGCTGA GAATGAGACTGCATGGAGGT 50 463
E4 CAGTGGAGGTGAAGACTGGT CTGAAGGTCTACATGTCCAG 50 475
E5 GTGTCAAGATGCCTCAGTAT CTCTAGACCAGTGTACTAAC 50 419
E6 CTGAAGGAGGTTTGGGATGT CTCTGCACAGTTCTCTGAGA 50 412
E7 GAACAGCAGGGAGCATATGC CACACTGGAAGCTGCTGCTT 53 490
E8 CAGTTGCTTAGCTCTGGGAT ATGGAGGCATGCTGTCTCAG 50 449
E9 GTGGATACAAGCTGATTCTC CATAACCCACACTCTTACGC 53 430
E10 CTCCAGAATCCCATTATGAC CTACTATGAGCGTGCATTAC 50 460
E11 CTTGGTCACTTGACCAAAAG GTGACCGCATCAATCATAGA 50 457
E12 GCAACATCTCAGCTTACAAC CATGGAGAATTTGGCTTCTG 50 390
E13 CAGACTGTGGCTACTTGAGC CGAGAAGAACCCATCAGAGA 53 533
AT = annealing temperature.
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of deoxyribonucleoside and 1.25 U of AmpliTaq
Gold (Perkin Elmer, Roche Molecular Systems Inc,
Branchburg, NJ, USA) in a total volume of 50 μL.
The amplification conditions were 94°C for 5
minutes, followed by 35 cycles of 94°C for 45
seconds, annealing temperature for 45 seconds
and 72°C for 45 seconds, and extension at 72°C
for 10 minutes. The PCR products were examined
on 2% agarose gel and purified by QIAquick col-
umns (Qiagen Inc, Valencia, CA, USA), followed
by direct DNA sequencing with an ABI 377 auto-
matic sequencer (Applied Biosystems, Foster
City, CA, USA) with both forward and backward
primers.
Results
We identified three novel mutations (S277X in
the EXT1 gene and G194X and 939+1 g>a in the
EXT2 gene) (Figures 2–4) and one reported muta-
tion (Q172X in EXT2) (Table 2). According to the
criteria described by Cotton and Scriver,11 muta-
tions in coding sequences that generate stop
codons, frameshifts, or splicing that create down-
stream stop codons result in functional hemizy-
gosity and are likely to result in a disease pheno-
type. Therefore, these mutations are potentially
disease-causing alleles.
Discussion
Hereditary multiple exostoses is a dominantly in-
herited skeletal disorder primarily affecting en-
chondral bone during growth. The disease is char-
acterized by the formation of numerous cartilage-
capped, benign bone tumors that are often accom-
panied by skeletal deformities and short stature.
HME is diagnosed during the first decade of life
in more than 80% of cases. Exostoses increase in
size and number until closure of the growth plate
at the end of puberty. The most serious complica-
tion of HME is malignant degeneration, generally
into chondrosarcoma. Osteosarcomas have also
been reported.2 Other variable features include
Figure 4. Automated DNA sequencing of the EXT2 gene revealed:
(A) heterozygous G to A transition in Case 3 with forward primer.
(B) Sequence from normal control; (C) sequence from patient using
backward primer. ▼ = the exon and intron boundary of exon 4 and
intron 4.
Figure 2. Automated DNA sequencing of the EXT1 gene revealed:
(A) heterozygous C to G transition (830C>G, S277X) in Case 1 with
forward primer. (B) Sequence from normal control; (C) sequence
from patient using backward primer.
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Figure 3. Automated DNA sequencing of the EXT2 gene revealed:
(A) heterozygous G to T transition (580G>T, G194X) in Case 2 with
forward primer. (B) Sequence from normal control.
  A
  B
  A
  B
  C
Exon 4 Intron 4
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Table 2. EXT1 and EXT2 gene mutations in patients with hereditary multiple exostoses
Case Inheritance Gene Location Mutation Nucleotide change Consequence
1 Familial EXT1 Exon 1 S277X 830C>G Nonsense
2 Sporadic EXT2 Exon 2 G194X 580G>T Nonsense
3 Familial EXT2 Intron 4 — 939+1 g>a Altered splicing
4 Familial EXT2 Exon 1 Q172X 514C>T Nonsense
short stature, limb length inequalities, nerve and
blood vessel compression, impaired articular func-
tion, bowing of the tubular bones and synosto-
ses.2,12 Chromosome abnormalities were found in
patients with sporadic or inherited exostoses13,14
with loss of heterozygosity on chromosomes 8, 11
and 19, reported in HME-related and non-HME-
related chondrosarcomas.5,15,16 These findings
suggest that EXT1, EXT2 and EXT3 may act as tu-
mor suppressor genes.
Most reported mutations of EXT1 (86/98) and
EXT2 (36/42) led to haploinsufficiency (nonsense
mutations, frameshifts, altered splicing).8,9 In this
study, analysis revealed a novel nonsense muta-
tion in EXT1 (S277X) and in EXT2 (G194X), and a
new splicing mutation (939+1 g>a) and a known
mutation (Q172X) in EXT2. The G to A transition
within a 5-prime splice donor site following exon
4 in Case 3 resulted in improper splicing of this
exon and produced a frameshift that led to a pre-
mature termination codon.
These results demonstrate that distinct EXT1
and EXT2 mutations are present in Taiwanese HME
patients. Mutation analysis in families with HME
allows for genetic counseling and prenatal
diagnosis.
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